Evidence map›Paper›PMID 39567768›Full record

ArticleBone marrow transplantation2025

The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience.

S Giammarco, R Maggi, Luca Di Marino, P Chiusolo, L Teofili, N Piccirilo, E Metafuni, M A Limongiello, S Leotta, G Milone and 10 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD.Hematology. American Society of Hematology. Education Program · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

S GiammarcoDipartimento di Scienze di Laboratorio ed Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
R MaggiSezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy.
Luca Di MarinoSezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy.ORCID http://orcid.org/0009-0007-7101-7423
P ChiusoloDipartimento di Scienze di Laboratorio ed Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0002-1355-1587
L TeofiliDipartimento di Scienze di Laboratorio ed Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0002-7214-1561
N PicciriloDipartimento di Scienze di Laboratorio ed Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0002-1688-1987
E MetafuniDipartimento di Scienze di Laboratorio ed Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0002-4780-1273
M A LimongielloDipartimento di Scienze di Laboratorio ed Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.ORCID http://orcid.org/0000-0001-7802-8554
S LeottaDivisione Clinicizzata di Ematologia con Trapianto di Midollo Osseo. Azienda ospedaliero-universitaria "Policlinico G. Rodolico - San Marco" Catania, Catania, Italy.
G MiloneDivisione Clinicizzata di Ematologia con Trapianto di Midollo Osseo. Azienda ospedaliero-universitaria "Policlinico G. Rodolico - San Marco" Catania, Catania, Italy.
A CupriDivisione Clinicizzata di Ematologia con Trapianto di Midollo Osseo. Azienda ospedaliero-universitaria "Policlinico G. Rodolico - San Marco" Catania, Catania, Italy.
I CutiniSOD terapie cellulari e medicina trasfusionale, Azienda Ospedaliera- Universitaria, Careggi, Firenze, Italy.ORCID http://orcid.org/0000-0003-3721-0004
R SaccardiSOD terapie cellulari e medicina trasfusionale, Azienda Ospedaliera- Universitaria, Careggi, Firenze, Italy.
C NozzoliSOD terapie cellulari e medicina trasfusionale, Azienda Ospedaliera- Universitaria, Careggi, Firenze, Italy.
R BoncompagniSOD terapie cellulari e medicina trasfusionale, Azienda Ospedaliera- Universitaria, Careggi, Firenze, Italy.
A GozziniSOD terapie cellulari e medicina trasfusionale, Azienda Ospedaliera- Universitaria, Careggi, Firenze, Italy.
B ScappiniHematology Department, Azienda Ospedaliera- Universitaria, Careggi, Firenze, Italy.
M PicciniHematology Department, Azienda Ospedaliera- Universitaria, Careggi, Firenze, Italy.
N S FracchiollaFondazione IRCCS Ca' Granda Ospedale Maggiore, Policlinico Milano, Italy.
S SicaDipartimento di Scienze di Laboratorio ed Infettivologiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. simona.sica@unicatt.it.ORCID http://orcid.org/0000-0003-2426-3465

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39567768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.